1.
|
14 p, 1.3 MB |
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
/
Sforzini, Luca (King's College London) ;
Worrell, Courtney (King's College London) ;
Kose, Melisa (King's College London) ;
Anderson, Ian M. (The University of Manchester and Manchester Academic Health Sciences Centre) ;
Aouizerate, Bruno (University of Bordeaux) ;
Arolt, Volker (University of Münster) ;
Bauer, Michael (University Hospital Carl Gustav Carus) ;
Baune, Bernhard T. (The University of Melbourne) ;
Cleare, Anthony J. (National Institute for Health Research Mental Health Biomedical Research Centre) ;
Cowen, Philip J. (University of Oxford) ;
Dinan, Timothy G. (University College Cork) ;
Fagiolini, Andrea (University of Siena) ;
Ferrier, I. Nicol (Newcastle University) ;
Hegerl, Ulrich (Goethe University) ;
Krystal, Andrew D. (Duke University School of Medicine) ;
Leboyer, Marion (Université Paris Est Creteil (UPEC)) ;
McAllister-Williams, R. Hamish (Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust) ;
McIntyre, Roger S. (Brain and Cognition Discovery Foundation) ;
Meyer-Lindenberg, Andreas (Heidelberg University) ;
Miller, Andrew H. (Emory University School of Medicine) ;
Nemeroff, Charles B. (University of Texas at Austin) ;
Normann, Claus (Medical Center - University of Freiburg) ;
Nutt, David (Imperial College) ;
Pallanti, Stefano (University of Florence) ;
Pani, Luca (VeraSci) ;
Penninx, Brenda W. J. H. (Vrije Universiteit and GGZinGeest) ;
Schatzberg, Alan F. (Stanford University) ;
Shelton, Richard C. (University of Alabama at Birmingham) ;
Yatham, Lakshmi N. (University of British Columbia) ;
Young, Allan H. (National Institute for Health Research Mental Health Biomedical Research Centre) ;
Zahn, Roland (National Institute for Health Research Mental Health Biomedical Research Centre) ;
Aislaitner, Georgios (Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)) ;
Butlen-Ducuing, Florence (European Medicines Agency) ;
Fletcher, Christine (Biostatistics, GlaxoSmithKline) ;
Haberkamp, Marion (Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)) ;
Laughren, Thomas (Laughren Psychopharm Consulting) ;
Mäntylä, Fanni-Laura (GAMIAN-Europe (Global Alliance of Mental Illness Advocacy Networks-Europe)) ;
Schruers, Koen (University of Leuven) ;
Thomson, Andrew (European Medicines Agency) ;
Arteaga-Henríquez, Gara (Hospital Universitari Vall d'Hebron) ;
Benedetti, Francesco (IRCCS Scientific Institute Ospedale San Raffaele) ;
Cash-Gibson, Lucinda (Hospital Universitari Vall d'Hebron) ;
Chae, Woo Ri (Charité - Universitätsmedizin Berlin) ;
De Smedt, Heidi (Janssen Research & Development) ;
Gold, Stefan M. (University Medical Center Hamburg-Eppendorf) ;
Hoogendijk, Witte J. G. (Erasmus University Medical Centre) ;
Mondragón, Valeria Jordán (Medical Director Neuroscience for Region Europe at Novartis Pharma) ;
Maron, Eduard (West Tallinn Central Hospital) ;
Martynowicz, Jadwiga (Janssen Research & Development) ;
Melloni, Elisa (IRCCS Scientific Institute Ospedale San Raffaele) ;
Otte, Christian (Charité - Universitätsmedizin Berlin) ;
Perez-Fuentes, Gabriela (Hospital Universitari Vall d'Hebron) ;
Poletti, Sara (IRCCS Scientific Institute Ospedale San Raffaele) ;
Schmidt, Mark E. (Janssen Pharmaceutica NV) ;
van de Ketterij, Edwin (European Infrastructure for Translational Medicine (EATRIS)) ;
Woo, Katherine (Janssen Research & Development) ;
Flossbach, Yanina (Novartis Pharma AG) ;
Ramos-Quiroga, Josep Antoni (Hospital Universitari Vall d'Hebron) ;
Savitz, Adam J. (Department of Neuroscience) ;
Pariante, Carmine M (National Institute for Health Research Mental Health Biomedical Research Centre) ;
Universitat Autònoma de Barcelona
Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the present document we used a Delphi-method-based consensus approach to define TRD and PRD and to serve as operational criteria for future clinical studies, especially if conducted for regulatory purposes. [...]
2021 - 10.1038/s41380-021-01381-x
Molecular psychiatry, Vol. 27 (december 2021) , p. 1286-1299
|
|